Gilead Sciences has received approval from the US Food and Drug Administration (FDA) to use Epclusa for treating chronic hepatitis C infection (HCV) in children aged six years and above.

Drug dose will depend on weight and liver function. Patients must weigh a minimum of 17kg for a prescription.

Epclusa is a pan-genotypic, protease inhibitor-free regimen. The drug received the US and European regulatory approvals in 2016 to treat adults with hepatitis C infection.

Gilead Sciences chief medical officer Merdad Parsey said: “Gilead’s continued commitment to HCV elimination includes bringing our medicines to the most difficult-to-cure populations and today’s decision by the FDA represents an important step toward that goal.

“With consistently high cure rates in clinical trials and in the real world, Epclusa has the potential to help many of the children living with HCV in the US.”

The latest FDA approval comes after the review of results from a Phase II clinical trial performed in 175 children receiving Epclusa for 12 weeks.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Efficacy analysis in 173 participants showed a cure rate (SVR12) of 93% in children aged 12 to <18 years with genotype 1 HCV infection, 100% in those with genotype 2, 3, 4 and 6.

In patients aged six to <12 years old, the SVR rate was 93% in those with genotype 1, 91% in genotype 3, and 100% in genotype 2 and genotype 4 HCV infection.

The safety profile of the drug in children aged six years and above was generally consistent with trial data in adults.

With Gilead’s drug, the most common adverse reactions in adults are headache and fatigue.

Earlier this month, Gilead agreed to acquire Forty Seven for $4.9bn.